[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A021502 - Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

What is the purpose of the study?

This randomized phase III trial studies combination chemotherapy and Atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.

Upstate Institutional Review Board (IRB) Number:

1186549

Study/Protocol ID:

A021502

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Rahul Seth, DO

What is involved if I participate?

  • Is transportation provided or reimbursed?
    No

Where will the study take place?

Upstate Cancer Center - All procedures
Oneida - All procedures
Oswego - All procedures

ClinicalTrials.Gov ID:

NCT02912559

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Nicole D Bunyea
Phone: 315-464-8276
Email: bunyean@upstate.edu

Return to Previous Page || Search Again

Top